These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 8509968)

  • 1. Behavioral contracting to improve adherence in patients with thalassemia.
    Koch DA; Giardina PJ; Ryan M; MacQueen M; Hilgartner MW
    J Pediatr Nurs; 1993 Apr; 8(2):106-11. PubMed ID: 8509968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ; Göbel U; Christaras A; Janssen G
    Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z; Fischer R; Treadwell M; Yamashita R; Fung EB; Calvelli L; Quirolo K; Foote D; Harmatz P; Vichinsky EP
    Ann N Y Acad Sci; 2005; 1054():486-91. PubMed ID: 16339703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Congenital anemia].
    Graubner UB; Schmidt P; Haas RJ
    Internist (Berl); 1994 Mar; 35(3):269-74. PubMed ID: 8175291
    [No Abstract]   [Full Text] [Related]  

  • 5. Compliance of deferoxamine injection in beta-thalassaemia major patients in Iran.
    Rashid M; Karimi M
    Transfus Med; 2012 Apr; 22(2):104-7. PubMed ID: 22212011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive long-term intravenous iron-chelation therapy with deferoxamine in thalassemic patients.
    Cianciulli P; Forte L; Sorrentino F; Palombi M; Papa G; Marciani MG
    Bone Marrow Transplant; 1993; 12 Suppl 1():5-8. PubMed ID: 8374563
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M; Moayedi B; Zakerinia M; Hamidi M; Karimi M; Maracy M; Amirghofran Z
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA; Taqi A; Deghaidi A
    Pediatr Hematol Oncol; 2004; 21(5):453-60. PubMed ID: 15205089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central venous line thrombosis in children and young adults with thalassemia major.
    Finkelstein Y; Yaniv I; Berant M; Zilber R; Garty BZ; Epstein O; Lahav J; Tamary H
    Pediatr Hematol Oncol; 2004; 21(5):375-81. PubMed ID: 15205080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease knowledge and treatment adherence among patients with thalassemia major and their mothers in Taiwan.
    Lee YL; Lin DT; Tsai SF
    J Clin Nurs; 2009 Feb; 18(4):529-38. PubMed ID: 19192002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Continuous subcutaneous deferoxamine infusions in thalassemia major. Improvement in glucose tolerance].
    Krüger N; Stubbe P; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1986 May; 111(18):698-701. PubMed ID: 3486106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravenous administration of deferoxamine in over-night hospitalization: efficacy and good psychological tolerance in thalassemic children].
    Bachelot C; Plantaz D
    Pediatrie; 1990; 45(9):619-23. PubMed ID: 2175425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis.
    Cianciulli P; Sorrentino F; Forte L; Palombi M; Papa G; Meloni C; Taccone Gallucci M; Casciani CU
    Haematologica; 1992; 77(6):514-5. PubMed ID: 1289188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration.
    Lombardo T; Ferro G; Frontini V; Percolla S
    Am J Hematol; 1996 Jan; 51(1):90-2. PubMed ID: 8571945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a pill-swallowing training intervention to improve antiretroviral medication adherence in pediatric patients with HIV/AIDS.
    Garvie PA; Lensing S; Rai SN
    Pediatrics; 2007 Apr; 119(4):e893-9. PubMed ID: 17353298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurophysiologic and intellectual evaluation of beta-thalassemia patients.
    Economou M; Zafeiriou DI; Kontopoulos E; Gompakis N; Koussi A; Perifanis V; Athanassiou-Metaxa M
    Brain Dev; 2006 Jan; 28(1):14-8. PubMed ID: 15925466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rubber band technique for slow subcutaneous infusion of desferrioxamine (Desferal).
    Hathirat P; Isarangkura P; Panthangkura W; Chuansumrit A; Sasanakul W; Kanasit R
    Birth Defects Orig Artic Ser; 1988; 23(5B):123-7. PubMed ID: 3390534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barriers to adherence of deferoxamine usage in sickle cell disease.
    Treadwell MJ; Law AW; Sung J; Hackney-Stephens E; Quirolo K; Murray E; Glendenning GA; Vichinsky E
    Pediatr Blood Cancer; 2005 May; 44(5):500-7. PubMed ID: 15602707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.
    Borgna-Pignatti C; Franchini M; Gandini G; Vassanelli A; De Gironcoli M; Aprili G
    Haematologica; 1998 Sep; 83(9):788-90. PubMed ID: 9825575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensory neural hearing loss in beta-thalassemia major patients treated with deferoxamine.
    Shamsian BS; Aminasnafi A; Moghadassian H; Gachkar L; Arzanian MT; Alavi S; Esfehani H; Garallahi F; Amini R
    Pediatr Hematol Oncol; 2008 Sep; 25(6):502-8. PubMed ID: 18728969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.